WASHINGTON, Oct. 14, 2015 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a
Fanapt® patent, number 9,157,121 ('121 patent), is now
listed in the U.S. Food and Drug Administration publication
Approved Drug Products With Therapeutic Equivalence Evaluations,
commonly known as the Orange Book. The '121 patent was issued
by the United States Patent and Trademark Office in October 2015 and expires in April 2030.
Prior to this newly listed patent, the Fanapt® Orange Book
listed patents were the U.S. composition of matter patent, the '432
patent, the '610 patent, the '776 patent, the '638 patent, the '255
patent, the '742 patent, the '256 patent, and the '254 patent,
expected to expire in November 2016,
September 2025, November 2027, August
2030, October 2030,
December 2030, January 2031, February
2031, and December 2031,
respectively.
About Vanda Pharmaceuticals Inc.
Vanda
Pharmaceuticals Inc. is a biopharmaceutical company focused on
the development and commercialization of products for the treatment
of central nervous system disorders. For more on Vanda, please
visit www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release are "forward-looking statements"
under the securities laws. Forward-looking statements are based
upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Important factors
that could cause actual results to differ materially from those
reflected in Vanda's forward-looking statements include, among
others, Vanda's assumptions regarding the life of the
Fanapt® patents and other factors that are
described in the "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections
of Vanda's annual report on Form 10-K for the fiscal year
ended December 31, 2014 and quarterly report on Form 10-Q for
the quarter ended June 30, 2015, which are on file with
the SEC and available on the SEC's website
at www.sec.gov. In addition to the risks described above and
in Vanda's annual report on Form 10-K and quarterly reports on Form
10-Q, other unknown or unpredictable factors also could affect
Vanda's results. There can be no assurance that the actual results
or developments anticipated by Vanda will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Vanda. Therefore, no assurance can
be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
Corporate Contact:
Jim
Kelly
Senior Vice President and Chief Financial
Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contact:
Laney Landsman
Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vanda-announces-listing-of-a-new-fanapt-patent-in-the-fda-orange-book-300159926.html
SOURCE Vanda Pharmaceuticals Inc.